Maraviroc: Difference between revisions
Jump to navigation
Jump to search
Ahmed Zaghw (talk | contribs) No edit summary |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Maraviroc}} | {{Maraviroc}} | ||
{{CMG}} | {{CMG}}; {{AE}} {{AZ}} | ||
==Overview== | ==Overview== | ||
'''Maraviroc''' (brand-named '''Selzentry''' in U.S.) is an [[antiretroviral drug]] in the CCR5 receptor [[antagonist]] class used in the treatment of [[HIV]] infection. It is also classed as an [[entry inhibitor]]. It also appeared to reduce [[graft-versus-host disease]] in patients treated with [[allogeneic bone marrow transplantation]] for [[leukemia]], in a phase 1/2 study.<ref>http://www.uphs.upenn.edu/news/News_Releases/2012/07/hiv/</ref><ref>Blocade of lymphocyte chemotaxis in visceral graft-versus-host disease, Ran Reshef et al., New England Journal of Medicine, 367:135 (July 12, 2012)</ref> | |||
==Category== | ==Category== | ||
Antiretroviral | |||
==US Brand Names== | ==US Brand Names== | ||
Selzentry<sup>®</sup> | |||
==FDA Package Insert== | ==FDA Package Insert== | ||
Revision as of 15:47, 3 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]
Overview
Maraviroc (brand-named Selzentry in U.S.) is an antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. It is also classed as an entry inhibitor. It also appeared to reduce graft-versus-host disease in patients treated with allogeneic bone marrow transplantation for leukemia, in a phase 1/2 study.[1][2]
Category
Antiretroviral
US Brand Names
Selzentry®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ http://www.uphs.upenn.edu/news/News_Releases/2012/07/hiv/
- ↑ Blocade of lymphocyte chemotaxis in visceral graft-versus-host disease, Ran Reshef et al., New England Journal of Medicine, 367:135 (July 12, 2012)